B of A Securities Maintains Buy on Vaxcyte, Raises Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry maintains a Buy rating on Vaxcyte (NASDAQ:PCVX) and raises the price target from $101 to $140.
September 04, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has reaffirmed its Buy rating on Vaxcyte and increased the price target from $101 to $140, indicating strong confidence in the company's future performance.
The reaffirmation of a Buy rating and a significant increase in the price target from $101 to $140 by B of A Securities suggests a positive outlook for Vaxcyte. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100